High-dose Interferon Alpha in Treatment of Patients with Malignant Melanoma, Monitoring of Predictive and Prognostic Biomarkers

Abstract

Malignant nmelanoma is a very immunogenic tumour. Immunotherapy with HDI is considered to be the only therapeutic modality so far that has been proven to prolong relapse-free survival and overall survival (in short-time criterion) in adjuvant setting.

However, the results of these trials are inconsistent and particular biomarkers of therapeutic response have not been defined yet.

Keywords

• Malignant melanoma
• Immunotherapy
• High-dose interferon
• Prognostic and predictive factors
• Serum VEGF